This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Safety, Tolerability, and Immunogenicity of a CpG/Alum Adjuvanted SARS-CoV-2 Recombinant Protein Vaccine (ZR202-CoV) in Healthy Adults: Preliminary Report of a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial (preprint)
ssrn; 2023.
Preprint
in English
| PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.4375619
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-SSRN
Language:
English
Year:
2023
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS